A recent article by Dr. Kristina M. L. Acri née Lybecker highlighted her research about the fiscal workability of state pharmaceutical importation programs from two important aspects. Dr. Acri’s whole paper is very good. I recommend you read it if you’re into policy and not sound bites. I noticed, however, that the comments on the article elicited some common myths about Canadian drug importation that are important to address if we’re going to really understand this issue.
Responding to Criticism of ‘State Pharmaceutical Importation Programs Threaten Patients and Innovation’
No Comments
Patent
- Enablement
- Fee Shifting
- Litigation
- Function and Structure in Computers: A Stakeholder’s View
- Don’t Get Caught In the Conflict: U.S. Versus Brazilian IP Transfer Pricing Rules
- Other Barks & Bites, Friday, February 21: Federal Circuit Upholds Damages Limit for Failure to Mark, India Signs IP Accord with U.S. and Copyright Office Announces Fee Increases
- Lessons of Wisdom Following Athena SCOTUS Denial and October 2019 Patent Eligibility Guidance Update
- Bayh-Dole 40: Celebrating the Past, Protecting the Future
Recent Posts
- Function and Structure in Computers: A Stakeholder’s View
- Don’t Get Caught In the Conflict: U.S. Versus Brazilian IP Transfer Pricing Rules
- Other Barks & Bites, Friday, February 21: Federal Circuit Upholds Damages Limit for Failure to Mark, India Signs IP Accord with U.S. and Copyright Office Announces Fee Increases
- Lessons of Wisdom Following Athena SCOTUS Denial and October 2019 Patent Eligibility Guidance Update
- Bayh-Dole 40: Celebrating the Past, Protecting the Future